Matinas BioPharma (MTNB) Misses Q3 EPS by 1c; Reports Cash and Cash Equivalents of $53.8M

Matinas BioPharma (NYSE: MTNB) reported Q3 EPS of ($0.03), $0.01 worse than the analyst estimate of ($0.02).

For earnings history and earnings-related data on Matinas BioPharma (MTNB) click here.

You May Also Be Interested In

• Faraday Future unveils nine robot models, prices start at $9,990
• Is the S&P 500 in an "earnings bubble"? Goldman weighs in
• Can global equities keep rising? UBS sees these factors driving upside